Allergoid–mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring

• Published in: Journal of allergy and clinical immunology Vol. 149; no. 1; pp. 212 - 222.e9
• Main Authors: Benito-Villalvilla, Cristina, Pérez-Diego, Mario, Angelina, Alba, Kisand, Kai, Rebane, Ana, Subiza, José Luis, Palomares, Oscar
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.01.2022
• Subjects: Adult; Allergen-specific immunotherapy; Allergoids - pharmacology; allergoid–mannan conjugates; Antigens, Plant; CD4-Positive T-Lymphocytes - immunology; Cell Differentiation - drug effects; Cells, Cultured; Cytokines - immunology; Dendritic Cells - immunology; Dendritic Cells - metabolism; Epigenesis, Genetic; epigenetics; Female; Humans; Immune Tolerance; Lipopolysaccharides - pharmacology; Male; Mannans - pharmacology; metabolism; monocytes; Monocytes - cytology; Monocytes - drug effects; Phleum; Pollen; regulatory T cells; tolerogenic dendritic cells; regulatory T cells; Mannan-tolDC; OXPHOS; mRNA; ChIP; epigenetics; LPS; NADH; IDO; DC-SIGN; PD-L1; miRNA; monocytes; hmoDC; H3K4me3; H3K27ac; SOCS; tolerogenic dendritic cells; AIT; FOXP3; allergoid–mannan conjugates; Allergen-specific immunotherapy; ROS; metabolism; MTA; LNA; DC; H3K27me3; HDAC

Allergoid–mannan conjugates are novel vaccines for allergen-specific immunotherapy being currently assayed in phase 2 clinical trials. Allergoid–mannan conjugates target dendritic cells (DCs) and generate functional forkhead box P3 (FOXP3)-positive Treg cells, but their capacity to reprogram monocyt...